Hoth Therapeutics (HOTH) said Tuesday interim results from a phase 2a trial of HT-001 showed that all patients met the primary efficacy endpoint.
The trial demonstrated improvements in skin toxicities caused by epidermal growth factor receptor inhibitors, with all patients maintaining full cancer treatment doses, the company said.
Hoth reported no treatment-related adverse effects, noting HT-001's safety and tolerability.
The company's shares were up over 94% in recent early Tuesday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.